NCT01415908终止3 期
A Prospective, Multi-center, Pivotal Trial for INFUSE® Bone Graft With CAPSTONE® Spinal System and Posterior Supplemental Fixation to Treat 1- or 2-level Advanced Degenerative Disease of the Lumbosacral Spine For a TLIF Approach
Medtronic Spinal and Biologics10 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2011年7月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 15
- 试验地点
- 10
- 主要终点
- Rate of Overall Success
研究概览
简要总结
This investigation will provide safety and effectiveness information on the use of INFUSE® Bone Graft with the CAPSTONE® Spinal System and CD HORIZON® Spinal System with a Transforaminal Lumbar Interbody Fusion (TLIF) surgical approach at one or two adjacent levels from L2-S1 to treat subjects with advanced degenerative disease of the lumbosacral spine.
详细描述
The study is a prospective, multi-national study that compares INFUSE® Bone Graft (investigational group) to autogenous bone graft (control group). Control group subjects will receive the same surgical treatment except for the use of autogenous bone graft (from the iliac crest) instead of INFUSE® Bone Graft. All sites will follow a common Clinical Investigational Plan (CIP) that consists of the protocol and accompanying case report forms, risk analysis, investigator's agreement, subject informed consent, institutional review board (IRB) certification, labeling, and monitoring information.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has advanced degenerative disease of the lumbosacral spine (L2 to S1) that results in radiculopathy secondary to nerve root compression, manifested by, History of radiating leg or buttock pain, paresthesias, numbness or weakness, or History of neurogenic claudication.
- •Has a history of low back pain
- •Has radiographic evidence of advanced degenerative lumbosacral disease, such as decreased disc height; herniated nucleus pulposus; hypertrophy or thickening of the ligamentum flavum, annulus fibrosis, or facet joint capsule; hypertrophied facet joints, facet joint space narrowing, or facet periarticular osteophyte formation; trefoil canal shape; or lateral(subarticular) stenosis; or vertebral endplate osteophyte formation; and at least one of the following:
- •Sagittal plane translation (slippage) of the superior (cranial) vertebral body anterior or posterior to the inferior (caudal) vertebral body greater than 3mm, or Coronal plane translation (slippage) of the superior (cranial) vertebral body lateral to the inferior (caudal) vertebral body greater than 3mm, or Narrowing (stenosis) of the lumbar spinal canal and/or intervertebral foramen
- •Has single-level or adjacent two-level involvement from L2 to S
- •Has preoperative Oswestry score ≥
- •Has preoperative back pain score of ≥ 6 based on the Preoperative Back and Leg Pain Questionnaire (pain intensity + pain frequency).
- •Has preoperative leg pain score of ≥ 6 based on the Preoperative Back and Leg Pain Questionnaire (pain intensity + pain frequency).
- •Is at least 18 years of age and skeletally mature at the time of surgery.
- •Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of six months.
- •Is willing and able to comply with the study plan and able to understand and sign the Subject Informed Consent Form.
排除标准
- •Requires spinal fusion at more than two lumbar levels or at two non-adjacent levels.
- •Has had a prior lumbar surgical fusion procedure at the involved or adjacent spinal levels.
- •Has significant lumbar instability, defined as sagittal or coronal plane listhesis greater than Grade 2 spondylolisthesis utilizing Meyerding's Classification (Meyerding, HW, 1932).
- •Has scoliosis greater than 30 degrees.
- •Has had a previous diagnosis of osteoporosis, osteopenia, or osteomalacia.
- •In addition, if the subject has any of the following risk factors, a DEXA scan should be performed to determine eligibility:
- •History of a non-traumatic hip or spine fracture. Female who is postmenopausal. Female over the age of
- •Male over the age of
- •If the DEXA T-score is -2.5 or lower, OR a T-score of -1.5 or lower WITH a history of a vertebral compression fracture, the subject is excluded.
- •Is morbidly obese, as defined as a Body Mass Index (BMI) >
- •Has an active malignancy or prior history of malignancy (except for basal cell carcinoma of the skin).
- •Has an overt or active bacterial infection, either local or systemic.
- •Has undergone systemic administration of any type of corticosteroid, anti-neoplastic, immunostimulating, or immunosuppressive agents within 30 days prior to implantation of the assigned treatment.
- •Has a history of clinically significant cardiac or hematologic disease.
- •Has a history of autoimmune disease known to affect bone metabolism or the spine. Examples include spondyloarthropathies (e.g., ankylosing spondylitis, Crohn's disease, and ulcerative colitis), juvenile arthritis, rheumatoid arthritis, Grave's disease, and Hashimoto's thyroiditis.
- •Has a medical disease or condition that would preclude accurate clinical evaluation of the safety and effectiveness of the treatments in this study, such as motor weakness, sensory loss, or painful conditions that inhibit normal ambulation or other activities of daily living.
- •Has a history of any endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis imperfecta).
- •Has chronic or acute renal and/or hepatic failure or prior history of renal and/or hepatic parenchymal disease.
- •Has a history of exposure to injectable collagen.
- •Has received any previous exposure to any/all BMPs of either human or animal extraction.
- •Has a history of hypersensitivity to collagen or protein pharmaceuticals (e.g., monoclonal antibodies or gamma globulins).
- •Has a history of any allergy resulting in anaphylaxis.
- •Has a history of allergy to bovine products.
- •Has a documented allergy or intolerance to titanium, titanium alloy, tantalum, tantalum alloy, or polyetheretherketone (PEEK).
- •Has any condition in which MRI scans are contraindicated (e.g., cardiac pacemaker, brain aneurysm clips).
- •Has any condition in which a gadolinium-contrast MRI is contraindicated (e.g., sickle cell anemia, renal failure).
- •Is mentally incompetent. If questionable, obtain psychiatric consult.
- •Has a 'Waddell Signs of Inorganic Behavior' score of 3 or greater.
- •Is a prisoner.
- •Is a tobacco user who does not agree to suspend tobacco use prior to surgery.
- •Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug abuse.
- •Has received treatment with an investigational therapy (drug, device and/or biologic) within 28 days prior to implantation surgery or such treatment is planned during the 24-month period following the study surgery.
- •Is pregnant or nursing. Female of child-bearing potential must agree not to become pregnant for one year following surgery.
- •Is a Worker's Compensation case or is involved in spinal litigation.
结局指标
主要结局
Rate of Overall Success
时间窗: 24 months
Rate of overall success is reported as percent of subjects who met all of the following criteria: 1. fusion at all treated levels (e.g., one level for a one level fusion and two levels for a two level fusion); 2. pain/disability (Oswestry Disability Index) success; 3. neurological status success; 4. no serious adverse event classified as "implant associated" or "implant/surgical procedure associated"; 5. no additional surgical procedure classified as a "failure."
次要结局
- Hospital Stay(During the time of hospital stay)
- Success Rate of Back Pain(24 months)
- Operative Time(Operative time was recorded from skin incision to wound closure)
- Success Rate of Oswestry Disability Index(24 months)
- Success Rate of Leg Pain(24 months)
- Success Rate of General Health Status(24 months)
- Blood Loss(During the operation, an average of 200 minutes for investigational group and 281.5 minutes for control group)
- Rate of Fusion Success(24 months)
- Success Rate of Neurological Status(24 months)
- Percent of Subjects Who Had Additional Surgical Procedures/Interventions(24 months)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
不适用
INFUSE® Bone Graft/ PEEK Interbody Spacer/ Anterior Cervical Plate Pivotal Clinical TrialDegenerative Disc DiseaseNCT00485173Medtronic Spinal and Biologics224
撤回
不适用
Clinical Study of INFUSE® Bone Graft Compared to Autogenous Bone Graft for Vertical Ridge AugmentationAlveolar Bone Loss in MandibleEdentulous Alveolar Ridge In MandibleNCT01308996Medtronic Spinal and Biologics
招募中
不适用
A Post Market Surveillance on INFUSE Bone GraftIntervertebral Disc DegenerationSpinal FusionLumbar Disc DiseaseNCT05299762Medtronic Spinal and Biologics600
撤回
3 期
Bone Healing Accelerant Versus Standard of Care for Open Tibia FracturesTibial FracturesNCT03826784Carmell Therapeutics Corporation
Unknown
不适用
A Clinical Trial to Evaluate the Safety and Effectiveness of MatrixOssTM Bone GraftDental DiseasesNCT05371535Collagen Matrix188